Therapeutic approaches such as the utilization of the CSF1/CSF1R inhibitor Pexidartinib (PLX3397) have shown promise in counteracting M2-type TAM polarization, thereby mitigating its tumor-promoting effects and demonstrating the potential for tumor growth and metastasis suppression through TAM polarization modulation (Fujiwara et al., 2021). Here, CSF1R is linked to neoplasm.